Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Thursday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 1.0 %

NYSE:BTX traded up $0.01 on Thursday, hitting $0.95. The company’s stock had a trading volume of 24,514 shares, compared to its average volume of 515,543. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10. The stock has a fifty day moving average of $1.19 and a two-hundred day moving average of $1.63. The firm has a market capitalization of $55.84 million, a P/E ratio of -0.42 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.